A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia

Myelodysplasia Clinical Trial

Official title:

A Phase I Dose Escalating Study of Bortezomib and Lenalidomide in Patients With Untreated or Previously Treated, Primary and Secondary Non 5q- Del Myelodysplasia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00580242
• Other study ID #: 07-006
• Secondary ID: RV-MDS-PI-0161
• Status: Completed
• Phase: Phase 1
• First received: December 20, 2007
• Last updated: March 6, 2012
• Start date: November 2007
• Est. completion date: March 2012

Study information

• Verified date: March 2012
• Source: Massachusetts General Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This study proposes using bortezomib in cohorts of 3-6 patients at the doses of 0.7, 1, and 1.3 mg/m2 on days 1, 4, 8, and 11 to determine the MTD in combination with lenalidomide 10 mg a day, for 21 days of a 28 day treatment cycle for patients with myelodysplastic syndrome.

Description:

Currently, there are no curative therapies for myelodysplasia except for allogeneic stem cell transplantation. Both lenalidomide and bortezomib have activity as single agents in patients with myelodysplasia. This study proposes using bortezomib in cohorts of 3-6 patients at the doses of 0.7, 1, and 1.3 mg/m2 on days 1, 4, 8, and 11 to determine the MTD in combination withlenalidomide 10 mg a day, for 21 days of a 28 day treatment cycle. The planned bortezomib doses have been evaluated in previous Phase I clinical studies in similar patient populations and have been safe and well tolerated in a twice-weekly schedule of administration. Lenalidomide has been shown to have efficacy in myelodysplasia. The combination of lenalidomide and bortezomib has been used in patients with multiple myeloma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: March 2012
• Est. primary completion date: March 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients may be untreated or previously treated.

• Age > 18 years

• Able to adhere to study schedule and other protocol requirements

• Unequivocal clinicopathologic diagnosis of myelodysplastic syndrome, non 5q- deletion.

• Patients may have had prior chemotherapy or radiotherapy for another malignancy or myelodysplasia as long as it was completed at least 4 weeks (6 weeks for nitrosureas) prior to initiation of therapy.

• ECOG performance status of 0-2 (Appendix 10.3)

• Life expectancy greater than 3 months

• Total bilirubin = 2.0 mg/dl, ALT and AST = 3 X the upper limit of normal (ULN), creatinine < 2.0 mg/dl all within 28 days prior to enrollment.

• Patients must give voluntary written informed consent and HIPAA authorization before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.

• Absolute neutrophil count > 0.5 x 10 (9)/l

• Platelet count > 30 x 10 (9)/l

• Prior treatment with 5-azacytidine is encouraged, but not required.

• Patients may have had prior treatment for MDS, including single agent lenalidomide or bortezomib.

• Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50mIU/ml within 10-14 days prior to and within 24 hours of prescribing lenalidomide and must commit to abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control,at least 4 weeks before starting taking lenalidomide. FCBP must agree to ongoing pregnancy testing. Men must agree not to father a child and agree to use a latex condom during sexual contact with a female of child bearing potential even if they have had a successful vasectomy.

• All study participants must be registered into the mandatory RevAssist Program®, and be willing and able to comply with the requirements of RevAssist®.

Exclusion Criteria:

• Ejection fraction < 40%

• Patients who have had a myocardial infarction within 6 months of enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant.

• Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the consent form.

• Any condition, including laboratory abnormalities, that in the opinion of the investigator places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.

• Patients with major surgery within the 28 days prior to trial enrollment.

• Patients with = Grade 2 peripheral neuropathy or active herpes infection

• Patients with an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, cirrhosis, chronic obstructive or restrictive pulmonary disease, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrythmia.

• Patients with secondary MDS that require concurrent therapy for the primary cancer diagnosis.

• The development of erythema nodosum as characterized by a desquamating rash while taking thalidomide or similar drugs.

• Patient with hypersensitivity to bortezomib, boron or mannitol.

• Female subject is pregnant or breast-feeding. . Lactating females must agree not to breast feed while taking lenalidomide.

• Patient has received an investigational drug within 28 days of enrollment.

• Known hypersensitivity to thalidomide or lenalidomide

• Concurrent use of other anti-cancer agents or treatments.

• Known positive for HIV

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Myelodysplasia
• Myelodysplastic Syndromes
• Preleukemia

Intervention

Drug:
• Bortezomib
First cohort: Bortezomib 0.7mg/m2 IV on Days on Days 1, 4, 8, and 11. Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
• Bortezomib
Second cohort: Bortezomib 1mg/m2 IV on Days 1, 4, 8, and 11 Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
• Bortezomib
Third Cohort: Bortezomib 1.3mg/m2 IV on Days 1, 4, 8, and 11 of each cycle Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
• Lenalidomide
Lenalidomide 10 mg PO QD on Days 1 -21 followed by a 7 day rest period

Locations

Country	Name	City	State
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (3)

Lead Sponsor	Collaborator
Massachusetts General Hospital	Celgene Corporation, Dana-Farber Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Establish the maximally tolerated dose of bortezomib, up to 1.3 mg/m2/day, that can be administered in combination with lenalidomide in patients with primary and secondary non 5q del myelodysplasia who are untreated or previously treated.		3, 6 and 9 months	No
Secondary	Assess efficacy in terms of the number of patients experiencing a decrease in blast percentage		3, 6 and 9 months	No
Secondary	Assess efficacy in terms of the number of patients experiencing a decrease in transfusion requirements		3, 6 and 9 months	No
Secondary	Determine the toxicity profile of bortezomib when used in combination with lenalidomide for patients with myelodysplasia		3, 6 and 9 months	Yes
Secondary	Determine the time (days) to transfusion independence		3, 6 and 9 months	No
Secondary	Determine the duration of response		3, 6 and 9 months	No
Secondary	Determine if molecular markers can predict responsiveness to treatment (for consenting patients)		3, 6 and 9 months	Yes